[go: up one dir, main page]

BRPI0406801A - Derivados de tieno-pirimidinodiona e uso dos mesmos na modulação de doenças autoimunes - Google Patents

Derivados de tieno-pirimidinodiona e uso dos mesmos na modulação de doenças autoimunes

Info

Publication number
BRPI0406801A
BRPI0406801A BR0406801-7A BRPI0406801A BRPI0406801A BR PI0406801 A BRPI0406801 A BR PI0406801A BR PI0406801 A BRPI0406801 A BR PI0406801A BR PI0406801 A BRPI0406801 A BR PI0406801A
Authority
BR
Brazil
Prior art keywords
thieno
autoimmune diseases
sup
pyrimidinedione derivatives
modulating autoimmune
Prior art date
Application number
BR0406801-7A
Other languages
English (en)
Inventor
Simon David Guile
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0406801A publication Critical patent/BRPI0406801A/pt
Publication of BRPI0406801B1 publication Critical patent/BRPI0406801B1/pt
Publication of BRPI0406801B8 publication Critical patent/BRPI0406801B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"DERIVADOS DE TIENO-PIRIMIDINODIONA E USO DOS MESMOS NA MODULAçãO DE DOENçAS AUTOIMUNES". A presente invenção se refere a derivados de tieno-pirimidinodiona de fórmula (1): em que R¬ 1¬ e R¬ 2¬ independentemente entre si, representam um grupo C~ 1-6~alquila, C~ 3-6~alquenila, C~ 3-5~cicloalquil-C~ 1-3~alquila ou C~ 3-6~cicloalquila; cada um dos quais podendo ser opcionalmente substituído por 1 a 3 átomos de halogênio; R¬ 3¬ é um grupo- CO-G ou SO~ 2~-G, onde G é um anel de 5 ou 6 membros contendo um átomo de nitrogênio e um segundo heteroátomo selecionado de oxigênio e enxofre adjacente ao nitrogênio; o anel sendo substituído por pelo menos um grupo conforme definido no relatório descritivo; Q é CR¬ 4¬R¬ 5¬, onde R¬ 4¬ é hidrogênio, flúor ou C~ 1-6~ alquila e R¬ 5¬ é hidrogênio, flúor ou hidróxi; e Ar é um sistema de anel aromático de 5 a 10 membros, em que até 4 átomos do anel podem ser heteroátomos, independentemente selecionados de nitrogênio, oxigênio e enxofre, o sistema de anel sendo opcionalmente substituído por um ou mais grupos definidos no presente relatório descritivo; assim como sais e solvatos farmaceuticamente aceitáveis do mesmo. São também descritos processos para a preparação de tais compostos, composições farmacêuticas contendo os mesmos e seu uso em procedimentos de terapia, particularmente, na terapia de imunossupressão.
BRPI0406801A 2003-01-17 2004-01-15 derivados de tieno-pirimidinodiona e uso dos mesmos na modulação de doenças autoimunes BRPI0406801B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0300119-5 2003-01-17
SE0300119A SE0300119D0 (sv) 2003-01-17 2003-01-17 Novel compounds
PCT/SE2004/000052 WO2004065394A1 (en) 2003-01-17 2004-01-15 Thienopyrimidinediones and their use in the modulation of autoimmune disease

Publications (3)

Publication Number Publication Date
BRPI0406801A true BRPI0406801A (pt) 2006-01-17
BRPI0406801B1 BRPI0406801B1 (pt) 2018-04-03
BRPI0406801B8 BRPI0406801B8 (pt) 2021-05-25

Family

ID=20290154

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0406801A BRPI0406801B8 (pt) 2003-01-17 2004-01-15 derivados de tieno-pirimidinodiona e uso dos mesmos na modulação de doenças autoimunes

Country Status (23)

Country Link
US (2) US7384951B2 (pt)
EP (1) EP1587812B1 (pt)
JP (1) JP4519121B2 (pt)
KR (2) KR20110125256A (pt)
CN (1) CN100334093C (pt)
AT (1) ATE335748T1 (pt)
AU (1) AU2004206012B2 (pt)
BR (1) BRPI0406801B8 (pt)
CA (1) CA2512441C (pt)
DE (1) DE602004001857T2 (pt)
EG (1) EG25613A (pt)
ES (1) ES2270337T3 (pt)
IL (1) IL169370A (pt)
IS (1) IS2376B (pt)
MX (1) MXPA05007496A (pt)
NO (1) NO333702B1 (pt)
NZ (1) NZ541217A (pt)
PL (1) PL214682B1 (pt)
RU (1) RU2331647C2 (pt)
SE (1) SE0300119D0 (pt)
UA (1) UA81788C2 (pt)
WO (1) WO2004065394A1 (pt)
ZA (1) ZA200505364B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117583D0 (en) * 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
SE0300120D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
WO2004065395A1 (en) * 2003-01-17 2004-08-05 Astrazeneca Ab Thienopyridazinones and their use in modulation of autoimmune disease
AU2004308299B2 (en) 2003-12-19 2011-11-24 Plexxikon, Inc. Compounds and methods for development of Ret modulators
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
CA2608733A1 (en) 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
NZ565255A (en) 2005-06-22 2010-04-30 Plexxikon Inc Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
AU2007336811A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
GB0713479D0 (en) * 2007-07-11 2007-08-22 Syngenta Participations Ag Substituted aromatic heterocyclic compounds as fungicides
MX2010000617A (es) 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
WO2010109329A1 (en) * 2009-03-23 2010-09-30 Glenmark Pharmaceuticals, S.A. Furopyrimidinedione derivatives as trpa1 modulators
CA2756534A1 (en) * 2009-03-23 2010-09-30 Glenmark Pharmaceuticals, S.A. Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
AU2010232670B2 (en) 2009-04-03 2015-07-09 F. Hoffmann-La Roche Ag Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
MA33975B1 (fr) 2009-11-06 2013-02-01 Plexxikon Inc Composés et méthodes de modulation des kinases et leurs indications d'emploi
HUE040136T2 (hu) 2011-02-07 2019-02-28 Plexxikon Inc Vegyületek és eljárások kináz modulációra és azok indikációi
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US9296728B2 (en) 2012-01-20 2016-03-29 Regents Of The University Of Minnesota Therapeutic compounds
WO2013112881A1 (en) 2012-01-27 2013-08-01 Thomas Jefferson University Mct protein inhibitor-related prognostic and therapeutic methods
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
WO2014172627A1 (en) 2013-04-19 2014-10-23 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
NZ718576A (en) * 2013-10-21 2019-11-29 Genosco Substituted pyrimidine compounds and their use as syk inhibitors
WO2016118825A1 (en) 2015-01-22 2016-07-28 The Scripps Research Institute Heterocyclic inhibitors of monocarboxylate transporters
UY36586A (es) * 2015-03-26 2016-10-31 Bayer Pharma AG Heterociclilmetiltienouracilos y uso de los mismos
KR101712838B1 (ko) * 2016-03-17 2017-03-07 주식회사 골프존 가상 골프 시뮬레이션 장치, 가상 골프를 위한 영상 구현 방법 및 이를 기록한 컴퓨팅 장치에 의해 판독 가능한 기록 매체
KR101712836B1 (ko) * 2016-03-17 2017-03-22 주식회사 골프존 가상 골프 시뮬레이션 장치, 가상 골프를 위한 영상 구현 방법 및 이를 기록한 컴퓨팅 장치에 의해 판독 가능한 기록 매체
KR101730536B1 (ko) * 2016-03-17 2017-05-02 주식회사 골프존 스크린 골프 시스템에서 구현되는 컨텐츠 전송 서비스 방법, 컨텐츠 전송 서비스를 위한 모바일 단말기의 제어방법 및 이를 기록한 컴퓨팅 장치에 의해 판독 가능한 기록매체
TWI823932B (zh) * 2018-05-11 2023-12-01 中國大陸商迪哲（江蘇）醫藥有限公司 三唑并嘧啶化合物及其在治療癌症中之用途
CN119080799B (zh) * 2024-09-27 2025-12-05 山东大学 一种n-羟基噻吩并嘧啶二酮类衍生物及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US738495A (en) * 1902-12-26 1903-09-08 William E Sherwood Thill-coupling.
US6469014B1 (en) * 1997-05-28 2002-10-22 Astrazeneca Ab Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy
SE9702001D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
IL136499A0 (en) 1997-12-05 2001-06-14 Astrazeneca Uk Ltd Astrazeneca Pyrrolo-, thieno-, furano- and pyrazolo-[3,4,d] pypyrrolo-, thieno-, furano- and pyrazolo-[3,4,d] pyridazinone compounds, process for their preparatioridaziones compounds, process for their preparation, pharmaceutical compositions containing them, a n, pharmaceutical compositions containing them, a process for prepating the pharmaceutical compositiprocess for preparing the pharmaceutical compositions, and use thereof ons, and use thereof
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
NZ509809A (en) * 1998-08-28 2002-11-26 Astrazeneca Ab Thienol[2,3-d]pyrimidinediones which exhibit immunosuppressive activity
ATE272642T1 (de) * 2000-05-04 2004-08-15 Astrazeneca Ab Thieno(2,3-d)pyrimidindione und ihre verwendung als pharmazeutische mittel
GB0117583D0 (en) * 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
GB0118479D0 (en) 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
SE0300120D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
WO2004065395A1 (en) * 2003-01-17 2004-08-05 Astrazeneca Ab Thienopyridazinones and their use in modulation of autoimmune disease

Also Published As

Publication number Publication date
DE602004001857D1 (de) 2006-09-21
JP2006516974A (ja) 2006-07-13
RU2005121494A (ru) 2006-02-10
NO333702B1 (no) 2013-08-26
RU2331647C2 (ru) 2008-08-20
ATE335748T1 (de) 2006-09-15
PL378222A1 (pl) 2006-03-20
ES2270337T3 (es) 2007-04-01
DE602004001857T2 (de) 2007-05-24
BRPI0406801B1 (pt) 2018-04-03
CA2512441C (en) 2012-01-03
EP1587812B1 (en) 2006-08-09
PL214682B1 (pl) 2013-09-30
EG25613A (en) 2012-03-22
MXPA05007496A (es) 2005-09-21
IL169370A0 (en) 2007-07-04
KR20110125256A (ko) 2011-11-18
WO2004065394A1 (en) 2004-08-05
US7384951B2 (en) 2008-06-10
US20060052400A1 (en) 2006-03-09
HK1081959A1 (en) 2006-05-26
US20080214579A1 (en) 2008-09-04
AU2004206012A1 (en) 2004-08-05
NO20053826D0 (no) 2005-08-15
SE0300119D0 (sv) 2003-01-17
CN1761672A (zh) 2006-04-19
BRPI0406801B8 (pt) 2021-05-25
UA81788C2 (uk) 2008-02-11
EP1587812A1 (en) 2005-10-26
IS7965A (is) 2005-07-29
CA2512441A1 (en) 2004-08-05
KR20050092760A (ko) 2005-09-22
IL169370A (en) 2011-05-31
NO20053826L (no) 2005-10-17
IS2376B (is) 2008-07-15
NZ541217A (en) 2008-05-30
AU2004206012B2 (en) 2007-06-14
ZA200505364B (en) 2006-09-27
CN100334093C (zh) 2007-08-29
KR101107486B1 (ko) 2012-01-19
JP4519121B2 (ja) 2010-08-04

Similar Documents

Publication Publication Date Title
BRPI0406801A (pt) Derivados de tieno-pirimidinodiona e uso dos mesmos na modulação de doenças autoimunes
IS6520A (is) Ný efnasambönd
IS6658A (is) Ný efnasambönd
EA200401526A1 (ru) Новые соединения и их применение
SE9902987D0 (sv) Novel compounds
SE0301700D0 (sv) Novel compounds
SE0302139D0 (sv) Novel compounds
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
EA200501332A1 (ru) Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38
ATE327977T1 (de) Tetrahydrochinolin-derivate als crth2 antagonisten
ATE316083T1 (de) Adamantanderivate
TW200613243A (en) Novel compounds
SE0402925D0 (sv) Novel Compounds
TW200604197A (en) New compounds
DE60301339D1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
SE0101038D0 (sv) Novel compounds
SE0303280D0 (sv) Novel compounds
DE60208694D1 (de) Piperidinylmorpholinylderivate als modulatoren der aktivität des chemokinrezeptors
SE0401763D0 (sv) Compounds
ATE274515T1 (de) Pyrazolopyridinderivate
SE0302755D0 (sv) Novel compounds
SE0202693D0 (sv) Compounds
SE0403118D0 (sv) New compounds 2
MXPA05007495A (es) Tienopiridazinonas y su uso en la modulacion de enfermedades autoinmunes.
IL172538A0 (en) Depsipeptide compounds, pharmaceutical compositions containing the same and processes for the preparation thereof

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06J Correction of requirement [chapter 6.10 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/01/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2653 DE 09-11-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.